OVERVIEW

The 7th Annual Meeting of the International Academy for Clinical Hematology (IACH) including the COMydAL, COLYM and MPNCo&D tracks is organized by CME Congresses Ltd and will be held from Sep 19 - 21, 2024 at Pullman Paris Tour Eiffel, Paris, Ile-de-France, France.

Description:
The field of hematology continues to make significant progress, even in these challenging times. We have seen fascinating developments, and especially in the fields of MDS, AML and ALL, Lymphoma, and MPN.

The 7th IACH Meeting will continue to serve as a unique forum where the most compelling and controversial topics facing clinicians in are presented. The program will provide a platform to interact and discuss with leading experts many key and developing issues in clinical hematology and within these specialized fields.

Main Topics:

  • Advances in disease biology
  • AML, ALL, MDS, MPNs, HL, NHL, CLL.. pathophysiology and therapy
  • Choice of therapy for elderly patients
  • Guidelines in specific clinical situations
  • Immunotherapy
  • Minimal residual disease in different settings
  • Novel small molecules
  • Ongoing clinical trials and future trials
  • Options for refractory diseases
  • Outcome prediction
  • Practical guidelines for the practicing physician
  • Prevention of relapse
  • Supportive care

Scientific Program

Thursday, September 19, 2024
 Hall A
IACH
 		 
08:30-09:00Welcome Coffee
09:00-10:20Transplant Workshop Part I 
Moderators:
09:00-09:20How to optimize the choice of the stem cell source and donor:
09:20-09:40Optimal choice of the conditioning regimen:
09:40-10:00Optimal GVHD prophylaxis:
10:00-10:20Diagnosis and management of acute GVHD:
10:20-10:30Short Break
10:30-12:00Transplant Workshop Part II 
Moderators:
10:30-10:50Chronic GVHD: prevention and management of long-term complications:
10:50-11:10Diagnosis and management of chronic GVHD:
11:10-11:30Early transplant complications: a focus on VOD diagnosis:
11:30-12:00Breaking bad news: communication skills in case of life-threatening clinical conditions
Panel discussion: All session faculty
12:00-12:45Lunch Break
 Hall A
IACH + COLYM
 		 Hall B
COMydAL + MPNCo&D
 
12:45-13:00Meeting Opening Message
 		  
13:00-14:30Session 1a:
Indolent lymphoma
 		13:00-14:30Session 1b:
Controversies in lower risk MDS
 
 Chair: Stefano Luminari, Italy Moderators: Amer Zeidan, USA; Valeria Santini, Italy
13:00-13:15Case Report13:00-13:15How do we define lower risk MDS in 2024?
Matteo Della Porta, Italy
13:15-13:30Q&A13:15-13:30Therapy of thrombocytopenic lower risk MDS?
Ioannis Kotsianidis, Greece
13:30-13:50Marginal zone lymphoma (MZL):
Luca Arcaini, Italy		13:30-13:45What is the first line therapy for non-del5q anaemic LR-MDS:
Sophie Park, UK
13:50-14:10Follicular lymphoma (FL):
TBA		13:45-14:00Is sequencing or combining therapies the better approach for lower risk MDS?
María Díez Campelo, Spain
14:10-14:30Panel discussion: All session faculty14:00-14:15How should we measure therapeutic benefit in lower risk MDS?
Pierre Fenaux, France
14:15-14:30Panel discussion: All session faculty
14:30-14:50Coffee Break
  14:50-15:20Industry-supported Meet the Expert Session
15:20-15:30Technical Break
15:30-17:00Session 2a:
Hodgkin lymphoma
 		15:30-17:00Session 2b:
Treatment of intermediate/higher-risk MF
 
 Chair: Mehdi Hamadani, USA Moderators: Florian Heidel, Germany; Tania Jain, USA
15:30-15:45Case Report15:30-15:50Review of JAKi in treatment of MF which drug when to use:
Naveen Pemmaraju, USA
15:45-16:00Q&A15:50-16:10Debate: Future therapy of MF should be a combination there is enough evidence
Yes: Adam Mead, UK
No: Florian Heidel, Germany
16:00-16:151st line treatment young/fit:
Farrukh Awan, USA		16:10-16:30SCT in MF: Review of current practice USA perspective – we will do more transplants:
Tania Jain, USA
16:15-16:301st line treatment old/unfit:
Graham Collins, UK		16:30-16:50SCT in MF: Global perspective and reflections – where do we stand?
Arnon Nagler, Israel
16:30-16:45Best salvage in R/R Hodgkin:
Nilanjan Ghosh, USA		16:50-17:00Panel discussion: All session faculty
16:45-17:00Panel discussion: All session faculty
17:00-17:15Short Coffee Break
17:15-18:45Session 3a:
Diffuse large B cell lymphoma (DLBCL)
 		17:15-18:45Session 3b:
Controversies in higher risk MDS
 
 Chair: Anna Sureda, Spain Moderators: Amer Zeidan, USA; Valeria Santini, Italy
17:15-17:30Case Report17:15-17:30Should we care about MRD in higher risk MDS?
Arjan van de Loosdrecht, Netherlands
17:30-17:45Q&A17:30-17:45How can we stop phase 3 trials from failing in higher risk MDS?
Lionel Adès, France
17:45-18:001st line treatment:
Andrew Davies, UK		17:45-18:00How does venetoclax fit in the management of higher risk MDS?
Amer Zeidan, USA
18:00-18:15Bispecific moAb:
Catherine Thieblemont, France		18:00-18:15Is immune checkpoint inhibition dead in higher-risk MDS and AML?
Shahram Kordasti, UK
18:15-18:30CAR T:
TBA		18:15-18:30Are oral HMAs a game changer in higher risk MDS?
Valeria Santini, Italy
18:30-18:45Panel discussion: All session faculty18:30-18:45Panel discussion: All session faculty
Friday, September 20, 2024
 Hall A
IACH + COLYM
 		 Hall B
COMydAL + MPNCo&D
 
08:15-08:30Welcome Coffee
08:30-10:00IACH Session: Sexual and emotional life in patients with hematological malignancies08:30-10:00Industry-supported Morning Symposium
Moderators:  
08:30-08:40Opening remarks (The Lancet Hematology Editor)
08:40-08:55Introduction and unmet needs:
08:55-09:10Diagnosis and treatment of sexual health-related issues:
09:10-09:25Sexual health-related psychological and emotional life post allogeneic stem cell transplantation:
09:25-09:45Specific concerns: STIs, LMIC, adolescents and young adults:
09:45-10:00Panel discussion: All session faculty
10:00-10:30Special IACH Lecture: How to get published:
10:00-10:30Coffee Break
10:30-12:00Session 4a:
T cell non-Hodgkin lymphoma (T-NHL)
 		10:30-12:00Session 4b:
Essential thrombocytosis (ET) in 2024: Current and future directions
 
 Chair: Mehdi Hamadani, USA Moderator: Claire Harrison, UK
10:10-10:25Case Report10:10-10:30Management of fatigue for MPN patients
Claire Woodley, UK
10:25-10:40Q&A10:30-10:50Update for treatment of higher-risk ET:
Claire Harrison, UK
10:40-11:00BV-CHP & beyond in 1st line T-NHL:
Matthew Lunning, USA		10:50-11:10Debate: Should JAK2-ET be treated differently from CALR-ET?
Yes:
Anna Godfrey, UK
No, all patients with ET should be treated in a homogeneous way:
Francesca Palandri, Italy
11:00-11:20Checkpoint inhibition or allografting for R/R NK/T-cell lymphomas:
Philipp Berning, Germany		11:00-11:30CALR: A new era of molecular targeting in ET: Review of pre-clinical & clinical data:
Bethan Psaila, UK
11:20-11:40Panel discussion: All session faculty11:30-11:40Panel discussion: All session faculty
13:05-13:45Lunch Break
13:45-14:45Industry-supported Lunch Symposium  
14:45-15:00Technical Break
15:00-16:30Session 5a:
Chronic lymphocytic leukemia (CLL)
 		15:00-16:30Session 5b:
Controversies in classification, risk stratification and response assessment in AML
 Chair: Mohamed Kharfan-Dabaja, USA Moderator: Amer Zeidan, USA
15:00-15:15Case Report15:00-15:15How do we risk stratify older patients with AML?
Christoph Röllig, Germany
15:15-15:30Q&A15:15-15:30What decisions should be made based on MRD in AML?
Coleman Lindsley, USA
15:30-15:50Front line therapy for CLL:
Farrukh Awan, USA		15:30-15:45Can (or should) response criteria of MDS and AML be harmonized?
Lisa Pleyer, Austria
15:50-16:10Transplant and cellular therapies in CLL:
TBA		15:45-16:00Should we have two pathologic systems for AML?
Alexa Siddon, USA
16:10-16:30Panel discussion: All session faculty16:00-16:30Panel discussion: All session faculty
16:30-16:50Coffee Break
16:50-18:20Session 6a:
Minimal residual disease (MRD)
 		16:50-18:20Session 6b:
MPN special situations and future directions
 Chair: Stefano Luminari, Italy Moderators: Ruben Mesa, USA; Deepti Radia, UK
16:50-17:05Case Report16:50-17:05Inflammation and MPNs: Novel observations:
Shahram Kordasti, UK
17:05-17:20Q&A17:05-17:25Pre-fibrotic MF: State-of-the-art updates:
Ruben Mesa, USA
17:20-17:35Positron emission tomography (PET):
TBA		17:25-17:40HES: Clinical updates and treatment paradigm:
Andreas Reiter, Germany
17:35-17:50Mantle cell lymphoma (MCL):
Christiane Pott, Germany		17:40-18:00Systemic mastocytosis: Updates on clinical trials:
Deepti Radia, UK
17:40-18:05Follicular lymphoma (FL):
TBA		18:00-18:20Panel discussion: All session faculty
18:05-18:20Panel discussion: All session faculty
18:20-19:00IACH Awards
 		  
Saturday, September 21, 2024
 Hall A
IACH + COLYM
 		 Hall B
COMydAL + MPNCo&D
 
08:15-08:30Welcome Coffee
08:30-10:00Session 7a:
Mantle cell lymphoma (MCL)
 		08:30-10:00Session 7b:
Controversies in the management of AML
 Chair: Mohamed Kharfan-Dabaja, USA Moderator: Amer Zeidan, USA
08:30-08:45Case Report08:30-08:45Doublets vs triplets in older AML patients?
Stephane De Botton, France
08:45-09:00Q&A08:45-09:00Which AML patients should we transplant in 2024?
TBA
09:00-09:20What is new in front-line management?
Madiha Iqbal, USA		09:00-09:15What to do with TP53 mutated higher risk MDS/AML?
Maximiian Stahl, USA
09:20-09:40Management of relapsed and/or refractory MCL:
Amer Beitinjaneh, USA		09:15-09:30Targeting novel mechanisms of resistance in AML:
Gabriel Ghiaur, USA
09:40-10:00Panel discussion: All session faculty09:30-09:45Should we use maintenance therapy post-transplant?
TBA
09:45-10:00Panel discussion: All session faculty
10:00-10:30Coffee Break
10:30-12:00IACH Session: Management of hard-to-treat patients 
Moderator: Mohamad Mohty, France
10:30-10:45Management of severe TMA:
10:45-11:00Management of severe CRS:
11:00-11:15Management of VOD in children:
11:15-11:30Management of VOD in adults:
11:30-12:00Panel discussion: All session faculty
12:00-12:45Lunch Break
12:45-14:15Session 8a:
Rare diseases
 		12:45-14:15Session 8b:
A new era of disease modification for polycythemia vera (PV)
 
 Chair: Anna Sureda, Spain Moderator: Naveen Pemmaraju, USA
12:45-13:00Case Report12:45-13:15Debate: All low-risk PV pateints who are able to should be offered IFN
Yes:
Tiziano Barbui, Italy
No:
Mary Frances McMullin, UK
13:00-13:15Q&A13:15-13:35What is a high-risk PV patient in 2024?
Alberto Alvarez-Larrán, Spain
13:15-13:35Post-transplant lymphoproliferative disorders (PTLD):
Susan Prockop, USA		13:35-13:55How can JAK2 VAF be incorporated into management of PV?
TBA
13:35-13:55Richter’s transformation:
TBA		13:55-14:15Panel discussion: All session faculty
13:55-14:15Panel discussion: All session faculty
14:15-15:45IACH Lectures 
Moderators: Mohamad Mohty, France; Arnon Nagler, Israel
14:15-14:40Bispecific antibodies in lymphoma:
14:40-15:05Update on therapy of elderly myeloma:
15:05-15:30Cellular therapy in acute leukemia:
15:30-15:45Panel discussion: All session faculty
15:45-16:00Meeting Closing Remarks
 

KEY DATES

Event Start Date
19 Sep, 2024
Event Start Date
Event End Date
21 Sep, 2024
Event End Date
Credits

This Course has been approved for a maximum of 13.5 EBAH-CME Credit Points.

  • 13.5 CME

    • SPEAKERS

    Matteo Giovanni Della Porta
    Matteo Giovanni Della Porta
    MDHematology
    Claire N. Harrison
    Claire N. Harrison
    MD, DM, FRCP, FRCPathHaematology
    Anna Godfrey
    Anna Godfrey
    Hematology
    Florian Heidel
    Florian Heidel
    MDHematology, Oncology, Internal Medicine
    Arnon Nagler
    Arnon Nagler
    MD, MScInternal Medicine, Haematology
    Ruben Mesa
    Ruben Mesa
    MD, FACPHematology, Medical Oncology, Oncology, Internal Medicine
    Nilanjan Ghosh
    Nilanjan Ghosh
    MD, PhDHematology, Medical Oncology, Internal Medicine
    Mehdi Hamadani
    Mehdi Hamadani
    MDHematology, Medical Oncology, Internal Medicine
    Anna Balari
    Anna Balari
    MD, PhDHaematology
    Bethan Psaila
    Bethan Psaila
    MD, MA, MBBS, MRCP, FRCPath, PhDHematology
    Mohamad Mohty
    Mohamad Mohty
    MD, PhDOncology, Hematology
    Naveen Pemmaraju
    Naveen Pemmaraju
    MDHaematology, Internal Medicine, Medical Oncology
    Amer Zeidan M. Zeidan
    Amer Zeidan M. Zeidan
    MBBS, MHSHaematology, Internal Medicine, Medical Oncology
    Maximilian Stahl
    Maximilian Stahl
    MDHematology, Medical Oncology, Internal Medicine
    Francesca Palandri
    Francesca Palandri
    MD, PhDHematology
    Valeria Santini
    Valeria Santini
    MDHaematology
    Mary Frances McMullin
    Mary Frances McMullin
    MD, FRCPath, FRCPOncology, Hematology Blood and Marrow Transplant
    Adam Mead
    Adam Mead
    PhD, MRCP, FRCPathHematology
    Alexa Siddon
    Alexa Siddon
    MDPathology - Anatomic/Pathology - Clinical, Hematology
    Maria Campelo
    Maria Campelo
    MD, PhDHematology
    Pierre Fenaux
    Pierre Fenaux
    MD, PhDHaematology, Internal Medicine
    Matthew Lunning
    Matthew Lunning
    DO, FACPMedical Oncology, Internal Medicine
    Sophie Park
    Sophie Park
    MD, PhDHematology
    Gabriel Ghiaur
    Gabriel Ghiaur
    MD, PhDHematology, Medical Oncology, Internal Medicine
    Catherine Thieblemont
    Catherine Thieblemont
    MD, PhDOncology, Haematology
    Arjan Loosdrecht
    Arjan Loosdrecht
    MD, PhDHematology
    Claire Woodley
    Claire Woodley
    Hematology Nurse, Nurse Practitioner
    Ioannis Kotsianidis
    Ioannis Kotsianidis
    MD, PhDHematology
    Lionel Ades
    Lionel Ades
    MD, PhDHematology
    Lisa Player
    Lisa Player
    MD, MSc, MBAInternal Medicine, Medical Oncology, Hematology
    Alberto Alvarez-Larran
    Alberto Alvarez-Larran
    MDHematology
    Mohamed A. Kharfan Dabaja
    Mohamed A. Kharfan Dabaja
    MD, MBAOncology, Haematology
    Christiane Pott
    Christiane Pott
    MD, PhDHematology
    Luca Arcaini
    Luca Arcaini
    MDHematology
    Shahram Kordasti
    Shahram Kordasti
    MSc, MD, PhDHematology
    Tiziano Barbui
    Tiziano Barbui
    MDHaematology
    Susan Prockop
    Susan Prockop
    MDPediatric Hematology Oncology, Pediatrics
    Amer Beitinjaneh
    Amer Beitinjaneh
    MD, MSc, MPH, FACPHematology, Medical Oncology, Internal Medicine
    Deepti Radia
    Deepti Radia
    MBBS, MRCPI, FRCPath, MScHematology
    Robert Lindsley
    Robert Lindsley
    MD, PhDMedical Oncology
    Philipp Berning
    Philipp Berning
    MDHematology, Oncology, Internal Medicine
    Andreas Reiter
    Andreas Reiter
    MDOncology, Haematology
    Stefano Luminari
    Stefano Luminari
    MDHematology, Medical Oncology
    Graham Collins
    Graham Collins
    MA, MRCP, FRCPath, DPhilHaematology
    Christoph Rollig
    Christoph Rollig
    MScOncology, Haematology, Internal Medicine
    Stephane De Botton
    Stephane De Botton
    MD, PhDOncology, Hematology Blood and Marrow Transplant

    TARGET AUDIENCE

    PhysicianScientistsStudentsResidentsNursesHematologist

    SPECIALITIES

    Haematology

    SUGGESTED HOTELS

    CONFERENCE VENUE

    LocationPullman Paris Tour Eiffel
    18 Avenue De Suffren, 22 Rue Jean Rey Entrée Au,

    CANCELLATION & REFUND POLICY

    Cancellation Policy:
    All cancellations must be faxed, electronically mailed or postmarked. Refund of registration fees will be as follows:

    Postmarked before until August 12, 2024– 100% refund (minus €50 handling fee).

    Postmarked from August 13, 2024 – 50% refund.

    No refund on cancellations sent after September 13, 2024.

    Quick Linksfooter

    Copyrights © 2026 eMedEvents Corporation, All Rights Reserved